Last reviewed · How we verify
Avandia (ROSIGLITAZONE)
Avandia (generic name: ROSIGLITAZONE) is a Peroxisome Proliferator Receptor gamma Agonist Small molecule drug developed by Woodward. It is currently FDA-approved (first approved 1999) for Treatment Refractory Type 2 Diabetes Mellitus.
Avandia, also known as rosiglitazone, is a small molecule that acts as a peroxisome proliferator-activated receptor gamma agonist. It has been studied for use in treating conditions such as Type 2 Diabetes and Asthma, and has been used in combination with other medications like insulin glargine and metformin.
At a glance
| Generic name | ROSIGLITAZONE |
|---|---|
| Sponsor | Woodward |
| Drug class | Peroxisome Proliferator Receptor gamma Agonist |
| Target | CDGSH iron-sulfur domain-containing protein 1 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1999 |
Approved indications
- Treatment Refractory Type 2 Diabetes Mellitus
Common side effects
- Nausea/Vomiting
- Anemia
- Edema
- Diarrhea
- Headache
- Dyspepsia
- Hypoglycemia (rosiglitazone + metformin)
- Hypoglycemia (rosiglitazone + insulin)
- Edema (rosiglitazone + insulin)
- Edema (rosiglitazone + metformin)
Serious adverse events
- Congestive Heart Failure
- Myocardial Infarction
- Myocardial Ischemia
- Sudden Death
- Fractures (women)
Drug interactions
- choline fenofibrate
- ciprofloxacin
- fenofibrate
- levofloxacin
- norfloxacin
- ofloxacin
Key clinical trials
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies (PHASE2)
- Dietary Fatty Acids As Complementary Therapy in Type 2 Diabetes Mellitus (PHASE1)
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- Rosiglitazone Adjunctive Therapy for Severe Malaria in Children (NA)
- BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Midazolam (PHASE1)
- Rosiglitazone in Treating Patients With Liposarcoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Avandia CI brief — competitive landscape report
- Avandia updates RSS · CI watch RSS
- Woodward portfolio CI
Frequently asked questions about Avandia
What is Avandia?
What is Avandia used for?
Who makes Avandia?
What is the generic name of Avandia?
What drug class is Avandia in?
When was Avandia approved?
What development phase is Avandia in?
What are the side effects of Avandia?
What does Avandia target?
Related
- Drug class: All Peroxisome Proliferator Receptor gamma Agonist drugs
- Target: All drugs targeting CDGSH iron-sulfur domain-containing protein 1
- Manufacturer: Woodward — full pipeline
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Treatment Refractory Type 2 Diabetes Mellitus
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing